<DOC>
	<DOCNO>NCT02674555</DOCNO>
	<brief_summary>This study investigate absorption , metabolism excretion [ 14C ] label ASP8273 subject solid tumor harbor EGFR mutation ( per local testing ) . This study consist two part ( A B ) .</brief_summary>
	<brief_title>A Study Investigate Absorption , Metabolism Excretion 14CASP8273 Subjects With Solid Tumors</brief_title>
	<detailed_description>This study consist two part ( A B ) . In Part A , eligible subject admit site day -1 remain confined site postdosing discharge criterion meet . Subjects receive single dose [ 14C ] ASP8273 solution study day 1 . Once Part A complete , subject may elect continue participation Part B . Subjects receive oral administration ASP8273 ( nonradiolabeled ) daily 28-day cycle .</detailed_description>
	<criteria>Subject histologically cytologically confirm metastatic locally advanced , unresectable solid tumor harbor EGFR mutation . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . Subject must meet follow criterion laboratory test perform within 7 day prior enrollment . In case multiple laboratory data within period , recent data use . Neutrophil count ≥ 1,000/mm3 Platelet count ≥ 7.5 × 104/mm3 Hemoglobin ≥ 9.0 g/dL Lymphocyte count ≥ 500/mm3 Estimated glomerular filtration rate ( eGFR ) &gt; 50 ml/min calculate CockcroftGault Method Total bilirubin ( TBL ) &lt; 1.5 × upper limit normal ( ULN ; except subject document Gilbert 's syndrome ) Aspartate aminotransferase ( AST ) ALT &lt; 3.0 × ULN Serum sodium level ≥ 130 mmol/L Female subject must either : Of nonchild bear potential : 1 . Postmenopausal ( define least 1 year without menses ) prior screen , 2 . Documented surgically sterile status post hysterectomy ( least 1 month prior screen ) . Or , childbearing potential : 1 . Agree try become pregnant study 28 day final study drug administration , 2 . Must negative serum pregnancy test screen day 1 , 3 . If heterosexually active must use two form birth control* ( least one must barrier method ) start screen throughout study period 28 day final study drug administration . Female subject must breastfeed screen study period , 28 day final study drug administration . Female subject must donate ovum start screen throughout study period , 28 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective contraception consist two form birth control* ( one must barrier method ) start screen continue throughout study period 90 day final study drug administration . Male subject must donate sperm start screen throughout study period 90 day final study drug administration . *Acceptable form birth control include : Established use oral , injected implant hormonal method contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . Subject ongoing toxicity ≥ Grade 2 ( Common Terminology Criteria Adverse Event [ CTCAE ] v4.03 ) attributable prior medication treat solid tumor ( except alopecia ) time screen . Subject known history serious hypersensitivity reaction ASP8273 , component formulation use . Subject receive investigational therapy within 28 day 5 halflives , whichever short , prior first dose study drug . Subject receive prior EGFR inhibitor within 6 day prior first dose study drug . Subject follow within 14 day prior first dose study drug : A treatment agent antitumor activity include chemotherapy , radiotherapy , immunotherapy A major surgical procedure ( study relate biopsy ) , major surgical plan occur study Blood transfusion hemopoietic factor therapy Evidence active infection require systemic therapy Subject symptomatic central nervous system ( CNS ) metastasis . Subject previously treat brain CNS metastases eligible provide subject recover acute effect radiotherapy require steroid , whole brain radiation therapy complete least 2 week prior study drug administration , stereotactic radiosurgery ( SRS ) complete least 1 week prior first dose study drug . Subject ≥ CTCAE v4.03 Grade 2 neuropathy . Subject known history positive test hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) . Subject known history positive test human immunodeficiency virus ( HIV ) infection . Subject history druginduced interstitial lung disease ( ILD ) evidence active ILD . Subject severe uncontrolled systemic disease include uncontrolled hypertension ( blood pressure &gt; 150/100 mmHg ) active bleeding diatheses . Subject ongoing cardiac arrhythmia Grade ≥ 2 uncontrolled atrial fibrillation grade . Subject currently Class 3 4 New York Heart Association congestive heart failure . Subject history severe/unstable angina , myocardial infarction , cerebrovascular accident within 6 month prior first dose study drug . Subject concurrent corneal disorder ophthalmologic condition , Investigator 's opinion , make subject unsuitable study participation ( e.g. , advanced cataract , glaucoma , subject unable undergo comprehensive ophthalmologic exam ) . Subject history gastrointestinal ulcer gastrointestinal bleeding within 3 month prior first dose study drug . Subject difficulty take oral medication digestive tract dysfunction inflammatory bowel disease would interfere intestinal absorption drug . Subject receive strong/moderate inhibitor inducer CYP3A4 within 14 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
	<keyword>Absorption</keyword>
	<keyword>[ 14C ] -radioactivity</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Oncology</keyword>
</DOC>